Conversely, some of the newly proposed therapies for AQP4-IgG NMO, such as sivelestat for inhibiting neutrophils[17], or eculizumab for inhibiting complement[30], are less likely to be needed in MOG-IgG NMO. This evidence concerns the gene AQP4 and neuromyelitis optica.